Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacques Moisan

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Frontiers in Immunology|June 19, 2026
Docetaxel enhances Vβ-directed T-cell activation and antitumor immunity mediated by a bifunctional TCR agonist in breast and prostate cancer modelsJonelle K Lee, Kellsye P Fabian, Ginette S Santiago-Sanchez, et al.
Science Advances|December 6, 2023
Innate TCRβ-chain engagement drives human T cells toward distinct memory-like effector phenotypes with immunotherapeutic potentialsPierre Vantourout, Josephine Eum, María Conde Poole, et al.
Journal for Immunotherapy of Cancer|July 1, 2026
PARP inhibition combined with a T-cell receptor β chain-directed antibody fusion molecule drives polyclonal antitumor immunity and tumor regressionGinette Santiago-Sanchez, Francesca Rosato, Kellsye P Fabian, et al.
Molecular Cancer Therapeutics|August 20, 2024
Dual A2A/A2B Adenosine Receptor Antagonist M1069 Counteracts Immunosuppressive Mechanisms of Adenosine and Reduces Tumor Growth In VivoKai Schiemann, Natalya Belousova, Armine Matevossian, et al.
Science Translational Medicine|November 29, 2023
A T cell receptor β chain-directed antibody fusion molecule activates and expands subsets of T cells to promote antitumor activityJonathan Hsu, Renee N Donahue, Madan Katragadda, et al.
Cancer Research|January 9, 2016
A Novel IL6 Antibody Sensitizes Multiple Tumor Types to Chemotherapy Including Trastuzumab-Resistant TumorsHaihong Zhong, April Davis, Maria Ouzounova, et al.
Journal of Molecular Biology|July 5, 2011
Whole-molecule antibody engineering: generation of a high-affinity anti-IL-6 antibody with extended pharmacokineticsDonna K Finch, Matthew A Sleeman, Jacques Moisan, et al.
Oncoimmunology|January 27, 2017
Synthetic RORγ agonists regulate multiple pathways to enhance antitumor immunityXiao Hu, Xikui Liu, Jacques Moisan, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 25, 2016
A CD80-Biased CTLA4-Ig Fusion Protein with Superior In Vivo Efficacy by Simultaneous Engineering of Affinity, Selectivity, Stability, and FcRn BindingJulie Douthwaite, Jacques Moisan, Cyril Privezentzev, et al.
Journal of Medicinal Chemistry|September 9, 2021
Discovery of LYC-55716: A Potent, Selective, and Orally Bioavailable Retinoic Acid Receptor-Related Orphan Receptor-γ (RORγ) Agonist for Use in Treating CancerThomas D Aicher, Chad A Van Huis, Alexander R Hurd, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Frontiers in Immunology|June 19, 2026
Docetaxel enhances Vβ-directed T-cell activation and antitumor immunity mediated by a bifunctional TCR agonist in breast and prostate cancer modelsJonelle K Lee, Kellsye P Fabian, Ginette S Santiago-Sanchez, et al.
Science Advances|December 6, 2023
Innate TCRβ-chain engagement drives human T cells toward distinct memory-like effector phenotypes with immunotherapeutic potentialsPierre Vantourout, Josephine Eum, María Conde Poole, et al.
Journal for Immunotherapy of Cancer|July 1, 2026
PARP inhibition combined with a T-cell receptor β chain-directed antibody fusion molecule drives polyclonal antitumor immunity and tumor regressionGinette Santiago-Sanchez, Francesca Rosato, Kellsye P Fabian, et al.
Molecular Cancer Therapeutics|August 20, 2024
Dual A2A/A2B Adenosine Receptor Antagonist M1069 Counteracts Immunosuppressive Mechanisms of Adenosine and Reduces Tumor Growth In VivoKai Schiemann, Natalya Belousova, Armine Matevossian, et al.
Science Translational Medicine|November 29, 2023
A T cell receptor β chain-directed antibody fusion molecule activates and expands subsets of T cells to promote antitumor activityJonathan Hsu, Renee N Donahue, Madan Katragadda, et al.
Cancer Research|January 9, 2016
A Novel IL6 Antibody Sensitizes Multiple Tumor Types to Chemotherapy Including Trastuzumab-Resistant TumorsHaihong Zhong, April Davis, Maria Ouzounova, et al.
Journal of Molecular Biology|July 5, 2011
Whole-molecule antibody engineering: generation of a high-affinity anti-IL-6 antibody with extended pharmacokineticsDonna K Finch, Matthew A Sleeman, Jacques Moisan, et al.
Oncoimmunology|January 27, 2017
Synthetic RORγ agonists regulate multiple pathways to enhance antitumor immunityXiao Hu, Xikui Liu, Jacques Moisan, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 25, 2016
A CD80-Biased CTLA4-Ig Fusion Protein with Superior In Vivo Efficacy by Simultaneous Engineering of Affinity, Selectivity, Stability, and FcRn BindingJulie Douthwaite, Jacques Moisan, Cyril Privezentzev, et al.
Journal of Medicinal Chemistry|September 9, 2021
Discovery of LYC-55716: A Potent, Selective, and Orally Bioavailable Retinoic Acid Receptor-Related Orphan Receptor-γ (RORγ) Agonist for Use in Treating CancerThomas D Aicher, Chad A Van Huis, Alexander R Hurd, et al.
Pageof 2